SCHEMBL10285461

SCHEMBL10285461

Cc1ccccc1-c1nc2ccc(F)c(F)c2nc1CNc1ncnc2[nH]cnc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 6/20 0.44
CYP2D6 P10635 7/20 0.34
CYP3A4 P08684 6/20 0.34
TSHR P16473 5/20 0.33
CYP2C19 P33261 5/20 0.33
CYP1A2 P05177 5/20 0.33
CLK4 Q9HAZ1 3/20 0.33
ALDH1A1 P00352 3/20 0.33
LMNA P02545 3/20 0.33
MAPK1 P28482 3/20 0.33
CYP2C9 P11712 3/20 0.33
USP2 O75604 2/20 0.33
ALOX15 P16050 2/20 0.33
BRAF P15056 2/20 0.33
MAPK13 O15264 2/20 0.33
MAPK12 P53778 2/20 0.33
MAPK11 Q15759 2/20 0.33
MAPK14 Q16539 2/20 0.33
KDR P35968 1/20 0.33
APEX1 P27695 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4174028 0.89 CLK4 (0.36) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL10286347 0.88 PIK3CD (0.52) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL4177698 0.85 CLK4 (0.36) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL12015594 0.85 PIK3CD (0.49) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL12015593 0.84 PIK3CD (0.48) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL10286281 0.84 PIK3CD (0.54) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL14850585 0.82 PIK3CD (0.48) PIK3CDMAPK1MAPTRAB9A
SCHEMBL4173738 0.80 PIK3CD (0.47) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL4173852 0.79 PIK3CD (0.38) PIK3CDCYP2D6CYP3A4TSHRCYP2C19
SCHEMBL19788583 0.78 PIK3CD (0.39) PIK3CDCYP2D6CYP3A4TSHRCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8193199-B2 Heterocyclic compounds and their uses AMGEN INC. (US) 2012-06-05 US disclosed
US-20090137581-A1 Heterocyclic compounds and their uses AMGEN INC. 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137581-A1 Heterocyclic compounds and their uses MCL1, BCL9, MALT1 PIK3CD 16/4885CYP2D6 2966/4885CYP3A4 3267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.